1. Miño de Kaspar H, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma. 2004;13(6):507-9.

2. Shiff FS. The shouting surgeons as a possible source of endophthalmitis. Ophthalmic Surg 1990; 21: 438-440.

3. Kattan HM, Flynn HW, Plugfelder SC, Robertson C, Forster RK. Nosocomial endophthalmitis Survey. Current incidence of infection after intraocular surgery. Ophthalmol 1991; 98: 227-238

4. Park SH, Lim JA, Choi JS, Kim KA, Joo CK. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. Cornea 2009; 28: 68-72.

5. Deramo VA, Lai JC, Fastenberg DM, Udell IJ. Acute Endophthalmitis in eyes treated prophylactically with Gatifloxacin and Moxifloxacin. Am J Ophthalmol 2006;142:721-725.

6. Mather R, Karenchak L, Romanowski E, Kowalski R. Fourth generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002; 133: 463-466.

7. Miño de Kaspar H, Koss MJ, He L, Blumenkranz M, N.Ta C. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol 2005; 139: 730-733.

8. MacMahon B., Trichopoulos D. Epidemiology: Principles and Methods. 2nd ed. Boston: Lippincott Williams & Wilkins; 1996.

9. Kowalski R, Yates K, Romanowski E, Karenchak L, Mah F, Gordon Y. An Ophthalmologist"™s Guide to Understanding Antibiotic Susceptibility and Minimum Inhibitory Concentration Data. Ophthalmology 2005; 112: 1987-1991.

10. Clinical and Laboratory Standards Institute. 2007. M100-S17. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.

11. New Technologies for Infection Diagnosis and Control Impacts of Antibiotic Resistant Bacteria. Office of Technology Assessment Congress of the United State. OTA-H-629 (Washington DC, US Government Printing Office, September 1995).

12. Yamada M, Hatou S, Yoshida J. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin. Eye Contact Lens. 2008 Mar;34(2):109-12.

13. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol 1996; 122: 1-17.

14. Puliafito CA, Baker AS, Haaf J, Foster CS. Infectious endophthalmitis. Review of 36 cases. Ophthalmol 1982; 89: 921-929.

15. Wilson FM. Causes and prevention of endophthalmitis. Int Ophthalmol Clin 1987; 27: 67-73.

16. Koss MJ, Eder M, Blumenkranz MS, et al.The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva Ophthalmologe. 2007;104:21-27.

17. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmol 2005;112:466-469.

18. Mather R, Karenchak LM, Romanowski EG et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002;133:463-466.

19. Kowalski RP, Dhaliwal DK, Krenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.